Global Strategic Investment Solutions LLC Sells 2,000 Shares of Catalent, Inc. (NYSE:CTLT)

Global Strategic Investment Solutions LLC reduced its position in Catalent, Inc. (NYSE:CTLT) by 29.8% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 4,718 shares of the company’s stock after selling 2,000 shares during the period. Global Strategic Investment Solutions LLC’s holdings in Catalent were worth $286,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Thurston Springer Miller Herd & Titak Inc. bought a new stake in shares of Catalent during the 2nd quarter worth about $42,000. Sentry Investment Management LLC acquired a new stake in shares of Catalent during the 3rd quarter worth $53,000. Longfellow Investment Management Co. LLC raised its stake in Catalent by 45.7% in the second quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company’s stock valued at $55,000 after purchasing an additional 305 shares in the last quarter. GAMMA Investing LLC lifted its position in Catalent by 25.9% during the second quarter. GAMMA Investing LLC now owns 1,032 shares of the company’s stock worth $58,000 after purchasing an additional 212 shares during the period. Finally, Intact Investment Management Inc. acquired a new stake in Catalent during the third quarter worth about $73,000.

Catalent Stock Up 0.1 %

CTLT traded up $0.08 during trading on Thursday, hitting $60.03. 301,274 shares of the company’s stock were exchanged, compared to its average volume of 2,041,098. The stock has a market cap of $10.90 billion, a P/E ratio of -10.92, a PEG ratio of 2.06 and a beta of 1.16. The business’s 50 day moving average is $60.03 and its two-hundred day moving average is $58.03. Catalent, Inc. has a fifty-two week low of $32.38 and a fifty-two week high of $61.20. The company has a quick ratio of 1.96, a current ratio of 2.52 and a debt-to-equity ratio of 1.35.

Catalent (NYSE:CTLT) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18). The company had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.06 billion. Catalent had a negative return on equity of 0.56% and a negative net margin of 22.72%. The business’s revenue for the quarter was up 4.2% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.10) earnings per share. As a group, equities analysts expect that Catalent, Inc. will post 0.95 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the company. William Blair restated a “market perform” rating on shares of Catalent in a research report on Tuesday, September 3rd. StockNews.com downgraded shares of Catalent from a “hold” rating to a “sell” rating in a research note on Wednesday. Baird R W downgraded Catalent from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $63.50 target price on shares of Catalent in a research note on Thursday, July 11th. Finally, Robert W. Baird reissued a “neutral” rating and issued a $63.50 price target on shares of Catalent in a research note on Tuesday, September 24th. One research analyst has rated the stock with a sell rating and eight have issued a hold rating to the company. According to data from MarketBeat.com, Catalent has a consensus rating of “Hold” and a consensus target price of $59.83.

Insider Buying and Selling

In other Catalent news, insider David Mcerlane sold 1,994 shares of Catalent stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $59.97, for a total transaction of $119,580.18. Following the transaction, the insider now directly owns 36,304 shares of the company’s stock, valued at $2,177,150.88. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.31% of the stock is currently owned by corporate insiders.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.